JP2024502820A5 - - Google Patents
Info
- Publication number
- JP2024502820A5 JP2024502820A5 JP2023540486A JP2023540486A JP2024502820A5 JP 2024502820 A5 JP2024502820 A5 JP 2024502820A5 JP 2023540486 A JP2023540486 A JP 2023540486A JP 2023540486 A JP2023540486 A JP 2023540486A JP 2024502820 A5 JP2024502820 A5 JP 2024502820A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hematopoietic
- grna
- cell
- offspring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132852P | 2020-12-31 | 2020-12-31 | |
| US63/132,852 | 2020-12-31 | ||
| PCT/US2021/065813 WO2022147347A1 (en) | 2020-12-31 | 2021-12-31 | Compositions and methods for cd34 gene modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502820A JP2024502820A (ja) | 2024-01-23 |
| JP2024502820A5 true JP2024502820A5 (https=) | 2025-01-15 |
Family
ID=81245941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540486A Pending JP2024502820A (ja) | 2020-12-31 | 2021-12-31 | Ｃｄ３４遺伝子改変のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240366675A1 (https=) |
| EP (1) | EP4271801A1 (https=) |
| JP (1) | JP2024502820A (https=) |
| KR (1) | KR20230126707A (https=) |
| CN (1) | CN116724109A (https=) |
| AU (1) | AU2021413252A1 (https=) |
| CA (1) | CA3202219A1 (https=) |
| WO (1) | WO2022147347A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN116656681B (zh) * | 2023-05-09 | 2024-03-19 | 佛山市第一人民医院 | 一种cd34转基因模式小鼠的构建方法与应用 |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| CN118325842B (zh) * | 2024-06-17 | 2025-01-24 | 天海元祺生物科技(天津)有限公司 | 一种工程化的细胞及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| WO2017079400A1 (en) * | 2015-11-04 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| LT3535392T (lt) * | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| CA3048434A1 (en) | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| WO2019106522A1 (en) * | 2017-11-28 | 2019-06-06 | Novartis Ag | Pooled crispr/cas9 screening in primary cells using guide swap technology |
| AU2018378479B2 (en) * | 2017-12-05 | 2025-03-13 | Vertex Pharmaceuticals Incorporated | CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof |
| EA202092044A1 (ru) | 2018-03-14 | 2021-03-03 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные рецепторы антигена против cd33 и их применения |
| WO2019200167A1 (en) * | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
-
2021
- 2021-12-31 JP JP2023540486A patent/JP2024502820A/ja active Pending
- 2021-12-31 CA CA3202219A patent/CA3202219A1/en active Pending
- 2021-12-31 AU AU2021413252A patent/AU2021413252A1/en not_active Abandoned
- 2021-12-31 CN CN202180087678.6A patent/CN116724109A/zh active Pending
- 2021-12-31 US US18/269,633 patent/US20240366675A1/en active Pending
- 2021-12-31 WO PCT/US2021/065813 patent/WO2022147347A1/en not_active Ceased
- 2021-12-31 KR KR1020237020742A patent/KR20230126707A/ko active Pending
- 2021-12-31 EP EP21854962.4A patent/EP4271801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024502820A5 (https=) | ||
| Ashmore-Harris et al. | The clinical potential of gene editing as a tool to engineer cell-based therapeutics | |
| JP7193862B2 (ja) | キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ－ｔ細胞の遺伝子編集 | |
| KR20190130608A (ko) | 면역종양학을 위한 조성물 및 방법 | |
| JP2022512882A (ja) | 抗ｃｄ３３免疫細胞癌療法 | |
| TW202425951A (zh) | 脂質奈米顆粒藥物綴合物 | |
| JP2023541457A5 (https=) | ||
| JPH11505704A (ja) | アンチｃｄ−１９抗体の単鎖可変領域フラグメントを含む免疫コンジュゲート | |
| US20220380776A1 (en) | Base editor-mediated cd33 reduction to selectively protect therapeutic cells | |
| JP2022513586A (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| TW201722444A (zh) | 重組李斯特菌疫苗菌株及在癌症免疫治療中使用該菌株之方法 | |
| JP2022534813A5 (https=) | ||
| JP2023528415A5 (https=) | ||
| CA3216023A1 (en) | Adenoviral gene therapy vectors | |
| KR20210105344A (ko) | 암 치료용 물질 및 방법 | |
| CA3249466A1 (en) | MODIFIED RECEIVER SYSTEMS TARGETTING PSMA AND CA9 | |
| JP2023541458A5 (https=) | ||
| US20210363212A1 (en) | Genetically engineered car t cells that secret interleukin-12 and therapeutic uses thereof | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| WO2022228471A1 (zh) | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 | |
| EP4476267A2 (en) | Chimeric antigen receptors binding steap1 | |
| JP6429191B2 (ja) | アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用 | |
| EP1028754A1 (en) | Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells | |
| TW202304961A (zh) | 用於將治療劑遞送至受體細胞之組合物及方法 | |
| TW202442689A (zh) | 靶向ｐｓｍａ及ｃａ９之系統 |